JUN 10, 2020 8:22 PM PDT

A Highly Targeted Cancer Therapeutic

WRITTEN BY: Nouran Amin

A study led by researchers at USC School of Pharmacy discusses a way to engineer drugs that highly target malignant tissues without affecting surrounding healthy tissues. These engineered compounds are known as ‘antibody-drug conjugates’ or ADCs that lead the way to better therapeutics for diverse types of cancer.

Learn more:

"Using our approach, homogenous ADCs could be made through a single-step reaction in less than two hours, much faster and more efficiently than conventional approaches," says the study's Principal Investigator, Yong (Tiger) Zhang, Assistant Professor of Pharmacology and Pharmaceutical Sciences at the USC School of Pharmacy.

As of now, only eight ADC drugs have been approved by the FDA after countless clinical trials evaluating their efficacy and safety in treating leukemia, breast cancer, lung cancer and so much more. The findings were published in Science Advances and describes how ADCs include an antibody that hunts for cancer and that antibody has a chemical linker that is “linking it” to a drug eventually uniting them and eradicating the cancer. This is precisely what makes ADC such an engineered targeted approach.

"Our technology features a designer 'linker' component exclusively recognized by a human enzyme that can rapidly catalyze the conjugation of drug molecules to the antibodies at a defined position," he says. "In addition to its fast rate and high efficiency, our ADC technology offers a new type of linker for connecting the drugs to antibodies. This designer linker ensures stable attachment of the drug and rapid release of the drugs into target cells, making the generated ADCs safer and more efficacious."

Source:  Science Daily

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
JUN 16, 2020
Microbiology
A Bacterial Compound Could Become a Treatment for Parasitic Infections
JUN 16, 2020
A Bacterial Compound Could Become a Treatment for Parasitic Infections
The World Health Organization has estimated that parasitic infections cause over 48 million cases of illness and 59,000 ...
JUN 25, 2020
Drug Discovery & Development
Three New Molecular Targets for Epilepsy
JUN 25, 2020
Three New Molecular Targets for Epilepsy
A study lead by scientists at FutureNeuro discovered three new drugs hold the potential for targeting epilepsy. These dr ...
JUL 02, 2020
Drug Discovery & Development
Common Asthma Drug Could Treat Alzheimer's
JUL 02, 2020
Common Asthma Drug Could Treat Alzheimer's
Researchers from Lancaster University, England, have found that Salbutamol, a medication commonly used to treat asthma, ...
JUL 13, 2020
Drug Discovery & Development
Russia Completes First Human Trial for COVID-19 Vaccine
JUL 13, 2020
Russia Completes First Human Trial for COVID-19 Vaccine
The Sechenov University Center for Clinical Research in Moscow, Russia, has completed its first round of clinical trials ...
JUL 17, 2020
Drug Discovery & Development
Could Low-Dose Radiation Therapy Treat COVID-19?
JUL 17, 2020
Could Low-Dose Radiation Therapy Treat COVID-19?
Research from a century ago points towards the potential of low-dose radiation therapy (LDRT) for treating pneumonia. Ev ...
JUL 29, 2020
Health & Medicine
The Carrier Oil Matters When it Comes to CBD Products
JUL 29, 2020
The Carrier Oil Matters When it Comes to CBD Products
The type of oil that is used to extract and carry the medicinally active ingredients (cannabinoids and terpenes) in cann ...
Loading Comments...